CA2847665A1 - Methods and systems for measuring and using the oxidation-reduction potential of a biological sample - Google Patents
Methods and systems for measuring and using the oxidation-reduction potential of a biological sample Download PDFInfo
- Publication number
- CA2847665A1 CA2847665A1 CA2847665A CA2847665A CA2847665A1 CA 2847665 A1 CA2847665 A1 CA 2847665A1 CA 2847665 A CA2847665 A CA 2847665A CA 2847665 A CA2847665 A CA 2847665A CA 2847665 A1 CA2847665 A1 CA 2847665A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- measuring
- reference value
- corp
- status
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 421
- 230000033116 oxidation-reduction process Effects 0.000 title claims abstract description 90
- 239000012472 biological sample Substances 0.000 title abstract description 67
- 238000012360 testing method Methods 0.000 claims abstract description 115
- 239000012530 fluid Substances 0.000 claims abstract description 62
- 238000011282 treatment Methods 0.000 claims description 99
- 238000012544 monitoring process Methods 0.000 claims description 92
- 208000014674 injury Diseases 0.000 claims description 82
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 77
- 208000036119 Frailty Diseases 0.000 claims description 70
- 206010003549 asthenia Diseases 0.000 claims description 70
- 206010028980 Neoplasm Diseases 0.000 claims description 59
- 201000011510 cancer Diseases 0.000 claims description 54
- 239000010836 blood and blood product Substances 0.000 claims description 52
- 229940125691 blood product Drugs 0.000 claims description 50
- 208000015181 infectious disease Diseases 0.000 claims description 45
- 238000002560 therapeutic procedure Methods 0.000 claims description 45
- 208000035475 disorder Diseases 0.000 claims description 43
- 230000001965 increasing effect Effects 0.000 claims description 42
- 239000003963 antioxidant agent Substances 0.000 claims description 41
- 230000036542 oxidative stress Effects 0.000 claims description 40
- 230000003068 static effect Effects 0.000 claims description 40
- 206010040047 Sepsis Diseases 0.000 claims description 36
- 230000000172 allergic effect Effects 0.000 claims description 36
- 208000010668 atopic eczema Diseases 0.000 claims description 36
- 208000029028 brain injury Diseases 0.000 claims description 36
- 230000035935 pregnancy Effects 0.000 claims description 36
- 230000008733 trauma Effects 0.000 claims description 36
- 201000010099 disease Diseases 0.000 claims description 34
- 230000003078 antioxidant effect Effects 0.000 claims description 33
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 31
- 206010012601 diabetes mellitus Diseases 0.000 claims description 30
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 29
- 201000000660 Pyloric Stenosis Diseases 0.000 claims description 27
- 238000001631 haemodialysis Methods 0.000 claims description 26
- 230000000322 hemodialysis Effects 0.000 claims description 26
- 208000008589 Obesity Diseases 0.000 claims description 25
- 235000020824 obesity Nutrition 0.000 claims description 25
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 24
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 24
- 206010002091 Anaesthesia Diseases 0.000 claims description 22
- 230000037005 anaesthesia Effects 0.000 claims description 22
- 238000011161 development Methods 0.000 claims description 22
- 230000036541 health Effects 0.000 claims description 22
- 230000008736 traumatic injury Effects 0.000 claims description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 20
- 206010038687 Respiratory distress Diseases 0.000 claims description 20
- 230000003862 health status Effects 0.000 claims description 19
- 230000001590 oxidative effect Effects 0.000 claims description 19
- 230000008859 change Effects 0.000 claims description 18
- 238000012546 transfer Methods 0.000 claims description 18
- 208000028399 Critical Illness Diseases 0.000 claims description 17
- 230000003247 decreasing effect Effects 0.000 claims description 17
- 210000003754 fetus Anatomy 0.000 claims description 16
- 230000004580 weight loss Effects 0.000 claims description 16
- 230000002250 progressing effect Effects 0.000 claims description 15
- 239000003638 chemical reducing agent Substances 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 238000011319 anticancer therapy Methods 0.000 claims description 10
- 230000006870 function Effects 0.000 claims description 10
- 208000012902 Nervous system disease Diseases 0.000 claims description 9
- 230000037147 athletic performance Effects 0.000 claims description 9
- 230000003115 biocidal effect Effects 0.000 claims description 9
- 238000007599 discharging Methods 0.000 claims description 9
- 238000002637 fluid replacement therapy Methods 0.000 claims description 9
- 229910052742 iron Inorganic materials 0.000 claims description 9
- 230000000241 respiratory effect Effects 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 230000001605 fetal effect Effects 0.000 claims description 8
- 230000008901 benefit Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 230000007717 exclusion Effects 0.000 claims description 7
- 230000004792 oxidative damage Effects 0.000 claims description 7
- 201000011461 pre-eclampsia Diseases 0.000 claims description 7
- 238000012549 training Methods 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 238000009256 replacement therapy Methods 0.000 claims description 6
- 208000000995 spontaneous abortion Diseases 0.000 claims description 6
- 150000003431 steroids Chemical class 0.000 claims description 6
- 206010000234 Abortion spontaneous Diseases 0.000 claims description 5
- 208000002296 eclampsia Diseases 0.000 claims description 5
- 239000003527 fibrinolytic agent Substances 0.000 claims description 5
- 230000003480 fibrinolytic effect Effects 0.000 claims description 5
- 208000004104 gestational diabetes Diseases 0.000 claims description 5
- 208000015994 miscarriage Diseases 0.000 claims description 5
- 230000000747 cardiac effect Effects 0.000 claims description 4
- 238000005399 mechanical ventilation Methods 0.000 claims description 4
- 229930003347 Atropine Natural products 0.000 claims description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 238000002399 angioplasty Methods 0.000 claims description 3
- 229940124650 anti-cancer therapies Drugs 0.000 claims description 3
- 230000002590 anti-leukotriene effect Effects 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229940125715 antihistaminic agent Drugs 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 3
- 229960000396 atropine Drugs 0.000 claims description 3
- 229940124630 bronchodilator Drugs 0.000 claims description 3
- 239000000168 bronchodilator agent Substances 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 239000000850 decongestant Substances 0.000 claims description 3
- 229940124581 decongestants Drugs 0.000 claims description 3
- 235000020880 diabetic diet Nutrition 0.000 claims description 3
- 230000037406 food intake Effects 0.000 claims description 3
- 235000012631 food intake Nutrition 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 239000003538 oral antidiabetic agent Substances 0.000 claims description 3
- 229940127209 oral hypoglycaemic agent Drugs 0.000 claims description 3
- 238000002640 oxygen therapy Methods 0.000 claims description 3
- 230000002537 thrombolytic effect Effects 0.000 claims description 3
- 238000011861 anti-inflammatory therapy Methods 0.000 claims description 2
- 238000011230 antibody-based therapy Methods 0.000 claims description 2
- 230000036571 hydration Effects 0.000 claims description 2
- 238000006703 hydration reaction Methods 0.000 claims description 2
- 230000004202 respiratory function Effects 0.000 claims description 2
- 230000000630 rising effect Effects 0.000 claims description 2
- 239000000523 sample Substances 0.000 abstract description 74
- 230000007704 transition Effects 0.000 abstract description 7
- 210000001519 tissue Anatomy 0.000 description 44
- 210000004369 blood Anatomy 0.000 description 36
- 239000008280 blood Substances 0.000 description 36
- 235000006708 antioxidants Nutrition 0.000 description 34
- 238000005259 measurement Methods 0.000 description 34
- 210000002381 plasma Anatomy 0.000 description 32
- 230000006378 damage Effects 0.000 description 31
- 208000027418 Wounds and injury Diseases 0.000 description 27
- 238000011156 evaluation Methods 0.000 description 26
- 208000006011 Stroke Diseases 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 22
- 230000018109 developmental process Effects 0.000 description 21
- 208000016261 weight loss Diseases 0.000 description 15
- 210000001124 body fluid Anatomy 0.000 description 14
- 239000010839 body fluid Substances 0.000 description 14
- 239000003642 reactive oxygen metabolite Substances 0.000 description 14
- 230000000474 nursing effect Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 12
- 230000034994 death Effects 0.000 description 12
- 231100000517 death Toxicity 0.000 description 12
- 230000000472 traumatic effect Effects 0.000 description 12
- 206010019196 Head injury Diseases 0.000 description 10
- 206010020751 Hypersensitivity Diseases 0.000 description 10
- 230000000386 athletic effect Effects 0.000 description 10
- 230000000399 orthopedic effect Effects 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 239000000306 component Substances 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 238000004393 prognosis Methods 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 208000030961 allergic reaction Diseases 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 210000003296 saliva Anatomy 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000008175 fetal development Effects 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 239000007800 oxidant agent Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 208000010496 Heart Arrest Diseases 0.000 description 5
- 206010020100 Hip fracture Diseases 0.000 description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 238000010837 poor prognosis Methods 0.000 description 5
- 208000023504 respiratory system disease Diseases 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000009529 traumatic brain injury Effects 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 208000010718 Multiple Organ Failure Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000006851 antioxidant defense Effects 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- -1 lipid peroxides Chemical class 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000034486 Multi-organ failure Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000006931 brain damage Effects 0.000 description 3
- 231100000874 brain damage Toxicity 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000007845 reactive nitrogen species Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 210000001138 tear Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000036818 High risk pregnancy Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 101150016491 chsA gene Proteins 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 208000030941 fetal growth restriction Diseases 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000012959 renal replacement therapy Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 102100032956 Alpha-actinin-3 Human genes 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000013883 Blast injury Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010061386 Chest injury Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 206010016852 Foetal damage Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000797292 Homo sapiens Alpha-actinin-3 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022979 Iron excess Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027423 Metabolic alkalosis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 208000023637 Multiple injury Diseases 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 206010071368 Psychological trauma Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101100537532 Rattus norvegicus Tnni3 gene Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- 208000028979 Skull fracture Diseases 0.000 description 1
- 206010041738 Sports injury Diseases 0.000 description 1
- 208000029224 Thoracic injury Diseases 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 1
- 101710165323 Troponin T, cardiac muscle Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000006993 Weiss annulation reaction Methods 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 208000028004 allergic respiratory disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940124977 antiviral medication Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 238000011961 computed axial tomography Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229950006073 cotinine Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 231100000725 drug overdose Toxicity 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000009322 hypertrophic pyloric stenosis Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000009485 infantile hypertrophic 1 pyloric stenosis Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 238000001584 occupational therapy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000009183 running Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 210000001189 slow twitch fiber Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000009192 sprinting Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/4161—Systems measuring the voltage and using a constant current supply, e.g. chronopotentiometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/4166—Systems measuring a particular property of an electrolyte
- G01N27/4168—Oxidation-reduction potential, e.g. for chlorination of water
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7004—Stress
- G01N2800/7009—Oxidative stress
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Food Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Ecology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Business, Economics & Management (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Tourism & Hospitality (AREA)
- Child & Adolescent Psychology (AREA)
- Economics (AREA)
- Human Resources & Organizations (AREA)
- Marketing (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717511P | 2012-10-23 | 2012-10-23 | |
| US61/717,511 | 2012-10-23 | ||
| US201361868983P | 2013-08-22 | 2013-08-22 | |
| US61/868,983 | 2013-08-22 | ||
| PCT/US2013/066432 WO2014066533A2 (en) | 2012-10-23 | 2013-10-23 | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2847665A1 true CA2847665A1 (en) | 2014-04-23 |
Family
ID=50484353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2847665A Abandoned CA2847665A1 (en) | 2012-10-23 | 2013-10-23 | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9410913B2 (https=) |
| EP (1) | EP2885636B1 (https=) |
| KR (1) | KR20150079550A (https=) |
| CN (1) | CN104737014B (https=) |
| AU (1) | AU2013334616A1 (https=) |
| CA (1) | CA2847665A1 (https=) |
| HK (1) | HK1209184A1 (https=) |
| IL (1) | IL231837A0 (https=) |
| IN (1) | IN2015DN01707A (https=) |
| SG (1) | SG11201401110WA (https=) |
| WO (1) | WO2014066533A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8709709B2 (en) | 2007-05-18 | 2014-04-29 | Luoxis Diagnostics, Inc. | Measurement and uses of oxidative status |
| JP5330381B2 (ja) | 2007-05-18 | 2013-10-30 | インスティチュート フォー モレキュラー メディスン インコーポレイテッド | 酸化還元電位（ｏｒｐ）を測定及び使用する方法 |
| EA201390485A1 (ru) | 2011-02-28 | 2013-09-30 | Луоксис Дайэгностикс, Инк. | Способ и устройство для измерения окислительно-восстановительного потенциала |
| JP5985739B2 (ja) | 2012-04-19 | 2016-09-06 | アイトゥ バイオサイエンス インコーポレイテッドＡｙｔｕ ＢｉｏＳｃｉｅｎｃｅ，Ｉｎｃ． | 多層ゲル |
| US9410913B2 (en) | 2012-10-23 | 2016-08-09 | Aytu Bioscience, Inc. | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample |
| US10802032B2 (en) * | 2013-01-11 | 2020-10-13 | Barry W Festoff | Blood diagnostics for evaluating and predicting brain damage after a concussion or other head injury |
| US10424404B2 (en) | 2013-11-13 | 2019-09-24 | Dacadoo Ag | Automated health data acquisition, processing and communication system and method |
| EP3145407A4 (en) * | 2014-05-23 | 2018-02-07 | dacadoo ag | Automated health data acquisition, processing and communication system |
| WO2016085997A2 (en) * | 2014-11-25 | 2016-06-02 | Aytu Bioscience, Inc. | Determination of fertility potential from the oxidation-reduction potential of a biological sample |
| WO2016172344A1 (en) * | 2015-04-21 | 2016-10-27 | Aytu Bioscience, Inc. | Use of orp for characterizing stroke patients |
| TWI651531B (zh) * | 2016-04-07 | 2019-02-21 | Chang Gung Memorial Hospital,Chiayi | 用於檢測脫水的方法及設備 |
| TWI718284B (zh) | 2016-04-07 | 2021-02-11 | 美商零質量純水股份有限公司 | 太陽能加熱單元 |
| TWI817925B (zh) | 2016-05-20 | 2023-10-11 | 美商資源環球公司 | 用於水萃取控制之系統及方法及水產生之網路 |
| MX2020000464A (es) | 2017-07-14 | 2021-01-08 | Zero Mass Water Inc | Sistemas para el tratamiento controlado del agua con ozono y metodos relacionados. |
| US11026625B2 (en) | 2017-08-08 | 2021-06-08 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
| US11384517B2 (en) | 2017-09-05 | 2022-07-12 | Source Global, PBC | Systems and methods to produce liquid water extracted from air |
| WO2019050866A1 (en) | 2017-09-05 | 2019-03-14 | Zero Mass Water, Inc. | SYSTEMS AND METHODS FOR MANAGING THE PRODUCTION AND DISTRIBUTION OF LIQUID WATER EXTRACTED FROM AIR |
| WO2019071202A1 (en) | 2017-10-06 | 2019-04-11 | Zero Mass Water, Inc. | SYSTEMS FOR PRODUCING WATER WITH LOST HEAT AND ASSOCIATED METHODS |
| WO2019089770A1 (en) | 2017-10-31 | 2019-05-09 | Aytu Bioscience, Inc. | Methods for treatment of infertility in varicocele patients |
| WO2019113354A1 (en) | 2017-12-06 | 2019-06-13 | Zero Mass Water, Inc. | Systems for constructing hierarchical training data sets for use with machine-learning and related methods therefor |
| US10722210B2 (en) * | 2017-12-14 | 2020-07-28 | Siemens Healthcare Gmbh | Method for memorable image generation for anonymized three-dimensional medical image workflows |
| WO2019217974A1 (en) | 2018-05-11 | 2019-11-14 | Zero Mass Water, Inc. | Systems for generating water using exogenously generated heat, exogenously generated electricity, and exhaust process fluids and related methods therefor |
| US11285435B2 (en) | 2018-10-19 | 2022-03-29 | Source Global, PBC | Systems and methods for generating liquid water using highly efficient techniques that optimize production |
| US20200124566A1 (en) | 2018-10-22 | 2020-04-23 | Zero Mass Water, Inc. | Systems and methods for detecting and measuring oxidizing compounds in test fluids |
| AU2020262259B2 (en) | 2019-04-22 | 2025-09-11 | Source Global, PBC | Water vapor adsorption air drying system and method for generating liquid water from air |
| MX2023004915A (es) | 2020-10-27 | 2023-07-21 | Source Global Pbc | Sistemas y metodos para el tratamiento y almacenamiento de agua. |
| WO2022159443A1 (en) | 2021-01-19 | 2022-07-28 | Source Global, PBC | Systems and methods for generating water from air |
| USD1094637S1 (en) | 2021-04-21 | 2025-09-23 | Source Global, PBC | Water generation panel |
| CN118019984A (zh) * | 2021-08-18 | 2024-05-10 | 株式会社生物自由基研究所 | 身体衰弱的测试方法、身体衰弱的测试试剂、身体衰弱的治疗药候选物质的筛选方法、精神衰弱的测试方法、精神衰弱的测试试剂以及精神衰弱的治疗药候选物质的筛选方法 |
| US20230106608A1 (en) * | 2021-10-01 | 2023-04-06 | Sandya Subramanian | Artifact Removal from Electrodermal Activity Data |
| WO2023059834A1 (en) | 2021-10-08 | 2023-04-13 | Source Global, PBC | Systems and methods for water production, treatment, adjustment and storage |
| CN114881316B (zh) * | 2022-04-24 | 2023-06-16 | 上海玫克生储能科技有限公司 | 锂电池剩余寿命预测方法、系统、终端设备及存储介质 |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3874384A (en) * | 1971-11-01 | 1975-04-01 | American Hospital Supply Corp | Improved blood storage unit and method of storing blood |
| US3956094A (en) | 1974-03-29 | 1976-05-11 | Olin Corporation | Apparatus for monitoring available chlorine in swimming pools |
| US4053381A (en) | 1976-05-19 | 1977-10-11 | Eastman Kodak Company | Device for determining ionic activity of components of liquid drops |
| US4225410A (en) | 1978-12-04 | 1980-09-30 | Technicon Instruments Corporation | Integrated array of electrochemical sensors |
| US4299919A (en) | 1980-06-30 | 1981-11-10 | St. Louis University | Perfusate redox potential controller |
| DE3278334D1 (en) | 1981-10-23 | 1988-05-19 | Genetics Int Inc | Sensor for components of a liquid mixture |
| US4571292A (en) | 1982-08-12 | 1986-02-18 | Case Western Reserve University | Apparatus for electrochemical measurements |
| DE3312923A1 (de) | 1983-04-11 | 1984-10-11 | Boehringer Mannheim Gmbh, 6800 Mannheim | Elektrodenanordnung zur elektrochemischen analyse elektrolytischer bestandteile einer fluessigkeit |
| US5509410A (en) | 1983-06-06 | 1996-04-23 | Medisense, Inc. | Strip electrode including screen printing of a single layer |
| US5682884A (en) | 1983-05-05 | 1997-11-04 | Medisense, Inc. | Strip electrode with screen printing |
| JPS6062978A (ja) | 1983-09-14 | 1985-04-11 | Matsushita Electric Works Ltd | バイオセンサ |
| US5260321A (en) | 1984-11-12 | 1993-11-09 | Sandoz Ltd. | Use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins |
| US4963245A (en) | 1986-05-02 | 1990-10-16 | Ciba Corning Diagnostics Corp. | Unitary multiple electrode sensor |
| US4980043A (en) | 1986-12-11 | 1990-12-25 | Horiba, Ltd. | Reference electrode |
| US4865717A (en) | 1987-05-26 | 1989-09-12 | Transducer Research, Inc. | Electrochemical micro sensor |
| US5273639A (en) | 1988-03-31 | 1993-12-28 | Agency Of Industrial Science & Technology | Probe electrode |
| JPH0752170B2 (ja) | 1988-05-27 | 1995-06-05 | ダイキン工業株式会社 | 拡散制限膜保持具収容容器 |
| US5312590A (en) | 1989-04-24 | 1994-05-17 | National University Of Singapore | Amperometric sensor for single and multicomponent analysis |
| JP2506312Y2 (ja) | 1989-10-31 | 1996-08-07 | 豊田合成株式会社 | エレクトロクロミック素子 |
| CH681351A5 (https=) | 1990-04-12 | 1993-03-15 | Hans Baer Dr | |
| EP0455072B1 (de) | 1990-05-02 | 1995-08-30 | Pacesetter AB | Silberchlorid-Bezugselektrode |
| DE69127196T2 (de) | 1990-06-12 | 1998-01-02 | British Tech Group | Antioxidanttest |
| US5165406A (en) | 1990-09-13 | 1992-11-24 | Via Medical Corporation | Electrochemical sensor apparatus and method |
| JP2741511B2 (ja) | 1991-07-10 | 1998-04-22 | 日本特殊陶業株式会社 | 基準電極 |
| US5227307A (en) | 1991-07-26 | 1993-07-13 | Diagnostic Markers, Inc. | Test for the rapid evaluation of ischemic state |
| US5188715A (en) | 1991-09-16 | 1993-02-23 | Nalco Chemical Company | Condensate corrosion sensor |
| US5384031A (en) | 1992-04-29 | 1995-01-24 | Diametrics Medical, Inc. | Reference electrode |
| US5387329A (en) | 1993-04-09 | 1995-02-07 | Ciba Corning Diagnostics Corp. | Extended use planar sensors |
| CA2161531A1 (en) | 1993-04-30 | 1994-11-10 | Donald C. Malins | Dna profiles as an indicator of cellular redox potential and cancer risk |
| KR970001146B1 (ko) | 1993-07-16 | 1997-01-29 | 엘지전자 주식회사 | 가스측정용 바이오센서 및 그 제조방법 |
| GB9325189D0 (en) | 1993-12-08 | 1994-02-09 | Unilever Plc | Methods and apparatus for electrochemical measurements |
| DE4404130A1 (de) | 1994-02-09 | 1995-08-10 | Siemens Ag | Elektrochemische Bestimmung der Sauerstoffkonzentration |
| ES2119416T3 (es) | 1994-03-30 | 1998-10-01 | Pacesetter Ab | Dispositivo de medida del caudal sanguineo. |
| US5672811A (en) | 1994-04-21 | 1997-09-30 | Ngk Insulators, Ltd. | Method of measuring a gas component and sensing device for measuring the gas component |
| US5494562A (en) | 1994-06-27 | 1996-02-27 | Ciba Corning Diagnostics Corp. | Electrochemical sensors |
| JP3272882B2 (ja) | 1994-09-22 | 2002-04-08 | 松下電器産業株式会社 | バイオセンサおよびその製造方法 |
| US5832410A (en) | 1994-12-06 | 1998-11-03 | Lin; Shengfu | Method of using a computer to collect chemical signals directly |
| US5782879A (en) | 1995-06-02 | 1998-07-21 | Sulzer Intermedics Inc. | Apparatus and method for discriminating flow of blood in a cardiovascular system |
| SE9504233D0 (sv) | 1995-11-27 | 1995-11-27 | Pacesetter Ab | Implantable medical device |
| US5679532A (en) | 1995-12-13 | 1997-10-21 | University Technology Corporation | Serum ferritin as a predictor of the acute respiratory distress syndrome |
| JPH09178690A (ja) | 1995-12-26 | 1997-07-11 | Ngk Spark Plug Co Ltd | イオンセンサ及びイオン濃度測定方法 |
| US6241862B1 (en) | 1996-02-14 | 2001-06-05 | Inverness Medical Technology, Inc. | Disposable test strips with integrated reagent/blood separation layer |
| JP3117192B2 (ja) | 1996-04-09 | 2000-12-11 | 有限会社ホワイト | 酸化還元電位測定機能内蔵健康管理計 |
| JP3451517B2 (ja) | 1996-05-20 | 2003-09-29 | オムロン株式会社 | プレーナ型酵素センサ |
| SE9603569D0 (sv) | 1996-09-30 | 1996-09-30 | Pacesetter Ab | Electrochemical sensor |
| US6269261B1 (en) * | 1996-10-26 | 2001-07-31 | Yugen Kaisha Endo Process | Health care instrument containing oxidation-reduction potential measuring function |
| JP3529081B2 (ja) | 1996-12-20 | 2004-05-24 | 松下電器産業株式会社 | コレステロールセンサおよびその製造方法 |
| US6369106B1 (en) | 1996-12-26 | 2002-04-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of ischemic brain injuries with brain targeted anti oxidant compounds |
| JP3394262B2 (ja) | 1997-02-06 | 2003-04-07 | セラセンス、インク． | 小体積インビトロ被検体センサー |
| IL131873A0 (en) | 1997-03-13 | 2001-03-19 | First Opinion Corp | Disease management system |
| GB9712386D0 (en) | 1997-06-14 | 1997-08-13 | Univ Coventry | Biosensor |
| US6177260B1 (en) | 1997-07-11 | 2001-01-23 | The Hong Kong Polytechnic University | Measurement of antioxidant (reducing) power and/or antioxidant concentration |
| JPH1183797A (ja) | 1997-09-03 | 1999-03-26 | Yoshitaka Otomo | 生物用酸化還元電位測定装置 |
| US5906921A (en) | 1997-09-29 | 1999-05-25 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method for quantitative measurement of a substrate using the same |
| SE9703957D0 (sv) | 1997-10-29 | 1997-10-29 | Pacesetter Ab | Method and device for sensing |
| SE9703958D0 (sv) | 1997-10-29 | 1997-10-29 | Pacesetter Ab | Method and device for determination of concentration |
| US6429021B1 (en) | 1998-03-19 | 2002-08-06 | Amway Corporation | Antioxidant activity profile assay |
| US6340428B1 (en) | 1998-04-02 | 2002-01-22 | Matsushita Electric Industrial Co., Inc. | Device and method for determining the concentration of a substrate |
| EP1084409B1 (en) | 1998-06-01 | 2004-05-12 | Roche Diagnostics Corporation | Method and device for electrochemical immunoassay of multiple analytes |
| US6599746B1 (en) | 1998-06-04 | 2003-07-29 | Walter Gumbrecht | Calibration fluid for calibrating a sensor for measuring a blood value and methods for producing and using the fluid |
| US6720107B1 (en) | 1998-06-09 | 2004-04-13 | Farnow Technologies Pty. Ltd. | Redox gel battery |
| JP2000002683A (ja) | 1998-06-16 | 2000-01-07 | Nec Corp | バイオセンサ |
| JP3267936B2 (ja) | 1998-08-26 | 2002-03-25 | 松下電器産業株式会社 | バイオセンサ |
| JP2000088801A (ja) | 1998-09-09 | 2000-03-31 | Isao Sawamoto | 酸化還元電位測定装置及び方法 |
| DE19846148C2 (de) | 1998-10-01 | 2002-10-10 | Igor Popov | Verfahren zur Beurteilung der oxidativen Modifikation proteinhaltiger Stoffe mittels Messung ihrer antiradikalen Aktivität |
| US20050142613A1 (en) * | 1998-10-02 | 2005-06-30 | David Bar-Or | Test for the rapid evaluation of ischemic states and kits |
| JP4205792B2 (ja) | 1998-12-04 | 2009-01-07 | 日本碍子株式会社 | ＮＯｘ分解電極及びＮＯｘ濃度測定装置 |
| CA2378678C (en) | 1999-06-08 | 2009-08-04 | Broadley Technologies Corporation | Reference electrode having a microfluidic flowing liquid junction |
| AU762944B2 (en) | 1999-06-23 | 2003-07-10 | Cornell Research Foundation Inc. | Dehydration/rehydration of marked liposomes on a test device |
| DE19929264A1 (de) | 1999-06-25 | 2001-01-11 | Meinhard Knoll | Universaltransducer |
| JP2001021527A (ja) | 1999-07-02 | 2001-01-26 | Akebono Brake Res & Dev Center Ltd | 使い捨て型バイオセンサ |
| CA2347594C (en) | 1999-10-05 | 2006-11-28 | Matsushita Electric Industrial Co., Ltd. | Glucose sensor |
| US6616819B1 (en) | 1999-11-04 | 2003-09-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
| JP4436531B2 (ja) | 2000-04-06 | 2010-03-24 | 株式会社テクノメデイカ | 電位差測定用参照電極 |
| WO2002028348A2 (en) | 2000-10-04 | 2002-04-11 | The Children's Hospital Of Philadelphia | Compositions and methods for treatment of cystic fibrosis |
| JP4154884B2 (ja) | 2000-11-10 | 2008-09-24 | 慶孝 大友 | 酸化還元電位測定装置および方法 |
| US7144495B2 (en) * | 2000-12-13 | 2006-12-05 | Lifescan, Inc. | Electrochemical test strip with an integrated micro-needle and associated methods |
| US7267750B2 (en) | 2001-01-17 | 2007-09-11 | Matsushita Electric Industrial Co., Ltd. | Biosensor |
| US7015310B2 (en) | 2001-03-12 | 2006-03-21 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Oxidation reduction sensitive green fluorescent protein variants |
| US6793632B2 (en) | 2001-06-12 | 2004-09-21 | Lifescan, Inc. | Percutaneous biological fluid constituent sampling and measurement devices and methods |
| FR2829579A1 (fr) | 2001-09-11 | 2003-03-14 | Endogenics | Procede pour evaluer l'etat biologique d'un patient |
| US7063782B2 (en) | 2001-11-26 | 2006-06-20 | Ischemia Technologies, Inc. | Electrochemical detection of ischemia |
| JP3828012B2 (ja) | 2001-12-28 | 2006-09-27 | 株式会社堀場製作所 | 虫歯リスク評価装置 |
| US7132296B2 (en) | 2002-02-15 | 2006-11-07 | Medical Products Manufacturing, Llc | Method for assaying the antioxidant capacity of a sample |
| JP2004117084A (ja) | 2002-09-25 | 2004-04-15 | Tanita Corp | 電気化学測定装置 |
| AU2002951886A0 (en) | 2002-10-08 | 2002-10-24 | The Western Australian Centre For Pathology And Medical Research | A method for measuring antioxident status |
| WO2004044557A2 (en) | 2002-11-12 | 2004-05-27 | Argose, Inc. | Non-invasive measurement of analytes |
| GR1004535B (el) | 2003-01-27 | 2004-04-22 | Medicon Hellas A.E. | Αυτοματοποιημενη μεθοδος προσδιορισμου της ολικης αντιοξειδωτικης ικανοτητος (total antioxidant capacity -tac-), και της διορθωμενης ολικης αντιοξειδωτικης ικανοτητος (corr tac) σε βιολογικα υγρα καιεκχυλισματα τροφων και ποτων βασισμενη στην αναστολη οξειδωσεως της κροκινης |
| JP2004350861A (ja) | 2003-05-28 | 2004-12-16 | Tanita Corp | 健康管理装置 |
| US7276382B2 (en) * | 2003-10-02 | 2007-10-02 | Noboru Horiguchi | Blood testing method |
| CN1605869B (zh) * | 2003-10-09 | 2010-12-15 | 堀口政江 | 血液检查方法 |
| JP4088312B2 (ja) | 2003-10-30 | 2008-05-21 | アークレイ株式会社 | バイオセンサおよびその製造方法 |
| PL1685393T3 (pl) | 2003-10-31 | 2007-07-31 | Lifescan Scotland Ltd | Elektrochemiczny pasek testowy do zmniejszania efektu bezpośredniego prądu interferencyjnego |
| RU2241997C1 (ru) | 2003-11-18 | 2004-12-10 | Евсеев Максим Александрович | Способ определения окислительно-восстановительного потенциала стенки желудка и двенадцатиперстной кишки |
| EP1778592B1 (en) * | 2004-07-07 | 2013-07-31 | Disney Enterprises, Inc. | Process control oxidation |
| US7572356B2 (en) | 2004-08-31 | 2009-08-11 | Lifescan Scotland Limited | Electrochemical-based sensor with a redox polymer and redox enzyme entrapped by a dialysis membrane |
| KR100698961B1 (ko) * | 2005-02-04 | 2007-03-26 | 주식회사 아이센스 | 전기화학적 바이오센서 |
| US20060258973A1 (en) | 2005-04-27 | 2006-11-16 | Kevin Volt | Micro-current Iontophoretic Percutaneous Absorptive Patch |
| US20090000947A1 (en) | 2005-06-06 | 2009-01-01 | Nikkiso Co., Ltd. | Biosensor and Biosensor Cell |
| DE202005009988U1 (de) | 2005-06-25 | 2005-10-13 | Rasche, Erich | Messpipette zur Redoxmessung von Kapillarblut |
| JP4623374B2 (ja) | 2005-08-26 | 2011-02-02 | 国立大学法人九州大学 | 化学感覚能センサチップ |
| GR1005561B (el) | 2005-10-03 | 2007-06-15 | Γεωργιος Κολιακος | Μετρηση της ολικης αντιοξειδωτικης ικανοτητος σε υγρα και διαλυμματα με τη χρηση της 3,3',5,5'-τετραμεθυλοβενζιδινης (τμβ) |
| WO2007059455A2 (en) | 2005-11-10 | 2007-05-24 | Virginia Commonwealth University | Non-biofouling, universal redox electrode and measurement system |
| JP4774941B2 (ja) | 2005-11-14 | 2011-09-21 | ソニー株式会社 | ゲル電解質およびゲル電解質電池 |
| EP1790356A1 (de) | 2005-11-24 | 2007-05-30 | Vifor (International) Ag | Präparat, umfassend Eisen(III)-Komplexverbindungen und redoxaktive Substanz(en) |
| EP1906178A1 (en) | 2006-09-26 | 2008-04-02 | F.Hoffmann-La Roche Ag | Method for detecting erroneous measurement results obtained with ion-selective electrodes |
| JP5330381B2 (ja) | 2007-05-18 | 2013-10-30 | インスティチュート フォー モレキュラー メディスン インコーポレイテッド | 酸化還元電位（ｏｒｐ）を測定及び使用する方法 |
| US8709709B2 (en) | 2007-05-18 | 2014-04-29 | Luoxis Diagnostics, Inc. | Measurement and uses of oxidative status |
| JP5164164B2 (ja) | 2008-10-20 | 2013-03-13 | 国立大学法人 筑波大学 | 微小参照電極デバイス |
| JP4650771B2 (ja) | 2008-11-11 | 2011-03-16 | 慶孝 大友 | 酸化還元電位測定装置 |
| US8758583B2 (en) | 2009-04-28 | 2014-06-24 | Abbott Diabetes Care Inc. | Smart sensor ports and methods of using same |
| JP5356337B2 (ja) | 2010-08-27 | 2013-12-04 | 株式会社堀場製作所 | 参照電極 |
| EA201390485A1 (ru) | 2011-02-28 | 2013-09-30 | Луоксис Дайэгностикс, Инк. | Способ и устройство для измерения окислительно-восстановительного потенциала |
| CN102192932B (zh) * | 2011-03-23 | 2013-10-02 | 天津市兰标电子科技发展有限公司 | 一种检测血样维生素含量的常规脉冲溶出法 |
| JP5985739B2 (ja) | 2012-04-19 | 2016-09-06 | アイトゥ バイオサイエンス インコーポレイテッドＡｙｔｕ ＢｉｏＳｃｉｅｎｃｅ，Ｉｎｃ． | 多層ゲル |
| US9410913B2 (en) | 2012-10-23 | 2016-08-09 | Aytu Bioscience, Inc. | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample |
-
2013
- 2013-10-23 US US14/061,436 patent/US9410913B2/en active Active
- 2013-10-23 EP EP13849118.8A patent/EP2885636B1/en not_active Not-in-force
- 2013-10-23 IN IN1707DEN2015 patent/IN2015DN01707A/en unknown
- 2013-10-23 HK HK15109839.9A patent/HK1209184A1/xx unknown
- 2013-10-23 US US14/061,482 patent/US9360446B2/en not_active Expired - Fee Related
- 2013-10-23 WO PCT/US2013/066432 patent/WO2014066533A2/en not_active Ceased
- 2013-10-23 KR KR1020157005187A patent/KR20150079550A/ko not_active Withdrawn
- 2013-10-23 AU AU2013334616A patent/AU2013334616A1/en not_active Abandoned
- 2013-10-23 SG SG11201401110WA patent/SG11201401110WA/en unknown
- 2013-10-23 CN CN201380054671.XA patent/CN104737014B/zh not_active Expired - Fee Related
- 2013-10-23 CA CA2847665A patent/CA2847665A1/en not_active Abandoned
-
2014
- 2014-03-31 IL IL231837A patent/IL231837A0/en unknown
-
2016
- 2016-05-05 US US15/147,554 patent/US10184931B2/en active Active
- 2016-07-02 US US15/201,424 patent/US20160313279A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160313279A1 (en) | 2016-10-27 |
| IL231837A0 (en) | 2014-08-31 |
| EP2885636A4 (en) | 2016-05-11 |
| US9410913B2 (en) | 2016-08-09 |
| HK1209184A1 (en) | 2016-03-24 |
| US20140110273A1 (en) | 2014-04-24 |
| KR20150079550A (ko) | 2015-07-08 |
| US10184931B2 (en) | 2019-01-22 |
| CN104737014A (zh) | 2015-06-24 |
| EP2885636B1 (en) | 2018-02-14 |
| IN2015DN01707A (https=) | 2015-05-22 |
| SG11201401110WA (en) | 2014-06-27 |
| EP2885636A2 (en) | 2015-06-24 |
| CN104737014B (zh) | 2018-03-27 |
| WO2014066533A3 (en) | 2014-07-17 |
| US9360446B2 (en) | 2016-06-07 |
| AU2013334616A1 (en) | 2014-06-26 |
| US20140121158A1 (en) | 2014-05-01 |
| US20170059549A1 (en) | 2017-03-02 |
| WO2014066533A2 (en) | 2014-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10184931B2 (en) | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample | |
| Jensen et al. | Racial differences in the incidence of and risk factors for atrial fibrillation in older adults: the cardiovascular health study | |
| Duan et al. | Semiquantitative cough strength score for predicting reintubation after planned extubation | |
| Serpa et al. | Validity of the Braden nutrition subscale in predicting pressure ulcer development | |
| Kubota et al. | Analyses of laboratory data and establishment of reference values and intervals for healthy elderly people | |
| Yavuz et al. | Identifying uncontrolled asthma in children with the childhood asthma control test or exhaled nitric oxide measurement | |
| Bayona et al. | Accuracy of high-resolution pharyngeal manometry metrics for predicting aspiration and residue in oropharyngeal dysphagia patients with poor pharyngeal contractility | |
| Hawkins et al. | Greater body mass index is associated with poorer cognitive functioning in male heart failure patients | |
| Gauvain et al. | Correlation between muscle mass and physical activity level in older adults at risk of falling: the FITNESS study | |
| Sakinah et al. | Development of a local malnutrition risk screening tool-hospital (MRST-H) for hospitalised elderly patients. | |
| Barben et al. | Mannitol dry powder challenge in comparison with exercise testing in children | |
| Chong et al. | Nasal high‐mobility group box 1 and caspase in bronchiolitis | |
| Hori et al. | Giant cell arteritis manifested by chronic dry cough | |
| Solanki et al. | Temporal trends and demographic variations in hospitalizations with angiodysplasia of the intestine: A US population based study. | |
| US20160313296A1 (en) | Use of orp for characterizing stroke patients | |
| US20130325356A1 (en) | Methods for determining hydration or dehydration level in a subject | |
| Rohimah et al. | Comparison of a simple nutrition screening tool (SNST) compared with subjective global assessment (SGA) in body mass index (BMI) assessments of type 2 diabetic patients validation of SNST versus BMI in T2 diabetes | |
| Chan et al. | The Effects of Whole-Body Exercise on Swallowing Function in Older Adults With Parkinson's Disease: A Proof-of-Principle Study | |
| Subías-Perié et al. | Prevalence of metabolic syndrome and association with physical activity and frailty status in Spanish older adults with decreased functional capacity: a cross-sectional study. Nutrients. 2022; 14 (11): 2302 | |
| Teng et al. | Knowledge and attitudes towards sarcopenia among healthcare professionals | |
| Qian et al. | Lower bioelectrical impedance phase angle is associated with COPD and is a marker for increased risks in elderly COPD patients | |
| Taylor et al. | Nonexercise Measurements as Predictors of Chronotropic Response to Exercise | |
| Giavina-Bianchi et al. | Development of a specific questionnaire for the suspicion of DPV | |
| Lazarević et al. | Unexpected cause of dyspnoea in a patient with allergic rhinitis | |
| Ochieng et al. | Discover Applied Sciences |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20181019 |
|
| FZDE | Discontinued |
Effective date: 20211116 |